Emmanuelle Mouton-barbosa

Title: Emmanuelle Mouton-Barbosa: Innovator in Cancer Research

Introduction

Emmanuelle Mouton-Barbosa is a prominent inventor based in Toulouse, France. She has made significant contributions to the field of cancer research, particularly in understanding the sensitivity to PI3K inhibitors. Her innovative work has the potential to impact treatment strategies for various cancers.

Latest Patents

Emmanuelle holds a patent for a "Marker for predicting the sensitivity to PI3K inhibitors." This invention addresses the challenges in predicting how different tumors respond to PI3K-targeting drugs. The patent identifies a phosphopeptide characterized by the amino acid sequence PGPSDHQSQEASQFER, with a phosphorylated threonine residue at position 3. This discovery provides valuable insights into managing the heterogeneity of PI3K expression patterns in tumor samples.

Career Highlights

Throughout her career, Emmanuelle has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paul Sabatier (Toulouse III). Her research has focused on the complexities of cancer signaling pathways and their implications for targeted therapies.

Collaborations

Emmanuelle has collaborated with notable colleagues, including Julie Guillermet-Guibert and Thibaut Douche. These partnerships have enhanced her research efforts and contributed to advancements in the understanding of cancer treatment.

Conclusion

Emmanuelle Mouton-Barbosa's work exemplifies the critical role of innovation in cancer research. Her patent on predicting sensitivity to PI3K inhibitors represents a significant advancement in the field. Through her career and collaborations, she continues to contribute to the fight against cancer.